| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/20/2013 | US20130157965 Prevention and Treatment of Oxidative Stress Disorders by Glutathione and Phase II Detoxification Enzymes |
| 06/20/2013 | US20130157950 Method for treating and/or preventing neurodegenerative disease by adiponectin receptor agonist |
| 06/20/2013 | US20130157947 Compounds for stem cell differentiation |
| 06/20/2013 | US20130157944 Treatment of Myocardial Infarction and Vascular Injury with Netrin-1 |
| 06/20/2013 | US20130157941 Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| 06/20/2013 | US20130157940 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 06/20/2013 | US20130157932 Ngal and urinary tract infection |
| 06/20/2013 | US20130157925 Compositions and methods for the treatment of cancer |
| 06/20/2013 | US20130157924 Reducing transmission of sexually transmitted infections |
| 06/20/2013 | US20130157339 Stabilized protease composition |
| 06/20/2013 | US20130156874 Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
| 06/20/2013 | US20130156872 Integrated Neuromodulation System for Mood Enhancement of a Living Human Subject |
| 06/20/2013 | US20130156870 Phytonutrient compositions and methods to protect against radical mediated cellular and dna damage |
| 06/20/2013 | US20130156869 Pharmaceutical composition for the treatment of alzheimer's disease, method for producing same and use thereof |
| 06/20/2013 | US20130156868 Nasal spray |
| 06/20/2013 | US20130156867 Artificial Tear Emulsion |
| 06/20/2013 | US20130156865 Potentiation induced by pde4 inhibitors in the treatment of leukemia |
| 06/20/2013 | US20130156857 Pharmaceutical Compositions Containing Diacerein |
| 06/20/2013 | US20130156855 Acne treatment |
| 06/20/2013 | US20130156854 Controlled Release Pharmaceutical Compositions of Milnacipran |
| 06/20/2013 | US20130156846 L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders |
| 06/20/2013 | US20130156845 Lipid formulated single stranded rna |
| 06/20/2013 | US20130156842 Bioadhesive drug formulations for oral transmucosal delivery |
| 06/20/2013 | US20130156835 Novel formulations of active ingredient(s) of plant origin or synthetic analogues thereof or of extract(s) of plant origin containing same, and of lecithin |
| 06/20/2013 | US20130156825 Modafinil Formulations |
| 06/20/2013 | US20130156821 Solid ganaxolone formulations and methods for the making and use thereof |
| 06/20/2013 | US20130156816 Methods and compositions for use in aquaculture |
| 06/20/2013 | US20130156815 Transdermal estrogen device and delivery |
| 06/20/2013 | US20130156814 Methods of treatment using tlr7 and/or tlr9 inhibitors |
| 06/20/2013 | US20130156811 Method of preventing early lawsonia intracellularis infections |
| 06/20/2013 | US20130156795 Methods for inhibition of cell proliferation, synergistic transcription modules and uses thereof |
| 06/20/2013 | US20130156794 Immunotherapy using redirected allogeneic cells |
| 06/20/2013 | US20130156793 Insulin-resistance-improving drug |
| 06/20/2013 | US20130156791 Methods and pharmaceutical compositions for the treatment of hiv-1 infections |
| 06/20/2013 | US20130156785 Novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases |
| 06/20/2013 | US20130156784 Compositions Using Antibodies Directed To GPNMB And Uses Thereof |
| 06/20/2013 | US20130156776 Compositions and methods for treating cancer and modulating stress granule formation |
| 06/20/2013 | US20130156768 Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases |
| 06/20/2013 | US20130156764 Neutralization of flt3 ligand as a leukemia therapy |
| 06/20/2013 | US20130156761 Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same |
| 06/20/2013 | US20130156757 Targeting vegf-b regulation of fatty acid transporters to modulate human diseases |
| 06/20/2013 | US20130156756 Substituted Triazolopyridines |
| 06/20/2013 | US20130156755 Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
| 06/20/2013 | US20130156753 THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| 06/20/2013 | US20130156746 Composition and method of manufacture |
| 06/20/2013 | US20130156739 Product for the upper gastric sphere |
| 06/20/2013 | US20130156735 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
| 06/20/2013 | US20130156732 Antiviral compounds |
| 06/20/2013 | US20130156731 Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
| 06/20/2013 | US20130156729 Mammalian Receptor Proteins; Related Reagents and Methods |
| 06/20/2013 | US20130156727 Indole derivatives as inhibitors of histone deacetylase |
| 06/20/2013 | US20130156725 Random pentapolymer for treatment of autoimmune diseases |
| 06/20/2013 | US20130156724 Use of poloxaminesines as inducers of the osteogenic differentiation of mesenchymal cells |
| 06/20/2013 | US20130156721 Cyclodextrin-based polymers for therapeutics delivery |
| 06/20/2013 | US20130156720 Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| 06/20/2013 | US20130156713 Compositions for enhancing nail health |
| 06/20/2013 | US20130156712 Stable surfactant compositions for suspending components |
| 06/20/2013 | US20130156710 Cyclohexyl carbamate compounds as skin and/or hair lightening actives |
| 06/20/2013 | US20130156707 Plant extracts made of sideritis and use thereof to boost cognitive performance |
| 06/20/2013 | US20130156702 Methods for the treatment and the diagnosis of cancer |
| 06/20/2013 | US20130156691 Antibody Therapy |
| 06/20/2013 | US20130152865 Nucleus coated with a film-forming coating having antibacterial and cicatrizing properties, and method for obtaining same |
| 06/20/2013 | DE102011088962A1 Wirkstoffkombinationen aus einer oder mehreren Carbonsäuren, insbesondereHydroxycarbonsäuren, und einer oder mehreren physiologisch unbedenklichen Hydroxamsäure sowie kosmetische oder dermatologische Zubereitungen, solcheWirkstoffkombinationen enthaltend Drug combinations of one or more carboxylic acids, insbesondereHydroxycarbonsäuren, and one or more physiologically acceptable hydroxamic acid as well as cosmetic or dermatological preparations such drug combinations containing |
| 06/20/2013 | DE102011088957A1 Wirkstoffkombinationen aus Pirocton Olamin und einer oder mehreren physiologischunbedenklichen Hydroxamsäure sowie kosmetische oder dermatologischeZubereitungen, solche Wirkstoffkombinationen enthaltend Active compound combinations of Pirocton olamine and one or more physiologically acceptable hydroxamic acid as well as cosmetic or dermatological preparations, such active ingredient combinations |
| 06/20/2013 | DE102011088951A1 Wirkstoffkombinationen aus einer oder mehreren aromatischen Alkoholen und einer oder mehreren physiologisch unbedenklichen Hydroxamsäuren sowie kosmetische oder dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend Drug combinations of one or more aromatic alcohols and one or more physiologically acceptable hydroxamic acids as well as cosmetic or dermatological preparations containing such active ingredient combinations |
| 06/20/2013 | DE102011088944A1 Active agent combination, useful e.g. to combat or prevent Staphylococcus aureus and as antibacterial, antimycotic or antiviral agents, comprises hydroxamic acids and silver compounds |
| 06/20/2013 | DE102011088936A1 Wirkstoffkombinationen aus einer oder mehreren Alkylethern des Glycerins und einer oder mehreren physiologisch unbedenklichen Hydroxamsäuren, sowie kosmetische oder dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend Drug combinations of one or more alkyl ethers of glycerol and one or more physiologically acceptable hydroxamic acids, as well as cosmetic or dermatological preparations containing such active ingredient combinations |
| 06/20/2013 | DE102011088934A1 Wirkstoffkombinationen aus einem oder mehreren Polyolen und einer oder mehreren physiologisch unbedenklichen Hydroxamsäuren, sowie kosmetische oder 10 dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend Drug combinations of one or more polyols and one or more physiologically acceptable hydroxamic acids, as well as cosmetic or dermatological preparations 10, such active ingredient combinations |
| 06/20/2013 | DE102011088931A1 Verwendung von Hydroxamsäuren zur Stabilisierung kosmetischer und oder dermatologischer Zubereitungen Use of hydroxamic acids to stabilize and cosmetic or dermatological preparations |
| 06/20/2013 | CA2858593A1 Use of polymeric excipients for lyophilization or freezing of particles |
| 06/20/2013 | CA2858531A1 Transdermal delivery system comprising buprenorphine |
| 06/20/2013 | CA2858025A1 Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor |
| 06/20/2013 | CA2857749A1 Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof |
| 06/20/2013 | CA2857603A1 Sulfonamide derivatives |
| 06/20/2013 | CA2857512A1 Novel heterocyclic compounds useful in sirtuin binding and modulation |
| 06/20/2013 | CA2857368A1 Method for extracting anthocyanin derivatives from a plant source |
| 06/20/2013 | CA2857337A1 Compositions containing kinase inhibitors |
| 06/20/2013 | CA2857302A1 Use of inhibitors of the activity or function of pi3k |
| 06/20/2013 | CA2857197A1 Novel glp-1 receptor modulators |
| 06/20/2013 | CA2857061A1 Novel benzopyran compounds, compositions and uses thereof |
| 06/20/2013 | CA2857057A1 Fluorinated estrogen receptor modulators and uses thereof |
| 06/20/2013 | CA2855940A1 Piperidinyl naphthylacetic acids |
| 06/20/2013 | CA2850706A1 Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound |
| 06/20/2013 | CA2849085A1 Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system |
| 06/20/2013 | CA2797904A1 Paste-like bone cement |
| 06/19/2013 | EP2604697A1 Triprenyl phenol compounds, process for their production and use as thrombolysis enhancer |
| 06/19/2013 | EP2604620A1 Modified fluorinated nucleoside analogues |
| 06/19/2013 | EP2604619A2 Mannose derivatives as antagonists of bacterial adhesion |
| 06/19/2013 | EP2604614A2 Oxidized phospholipids |
| 06/19/2013 | EP2604612A1 C-aryl glucoside derivatives, preparation rpocess and pharmaceutical use thereof |
| 06/19/2013 | EP2604611A1 N-Biaryl substituted diazabicycloalkane derivatives as agonists of the alpha7 and alpha4beta2 nACh Receptor |
| 06/19/2013 | EP2604610A1 Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof |
| 06/19/2013 | EP2604609A1 Aildenafil citrate crystal form o, preparation method and use thereof |
| 06/19/2013 | EP2604607A1 Prophylactic or therapeutic agent for non-alcoholic steatohepatitis |
| 06/19/2013 | EP2604606A1 Inhibitor of casein kinase 1 and casein kinase 1 |
| 06/19/2013 | EP2604605A2 Theanine derivative, preparation method thereof, and use thereof for alleviating acne |
| 06/19/2013 | EP2604604A1 Benzofuranyl derivatives used as glucokinase inhibitors |
| 06/19/2013 | EP2604603A1 Crystal forms of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide and methods for their preparation |
| 06/19/2013 | EP2604602A1 Heteroaryl-pyrazole derivative |
| 06/19/2013 | EP2604601A1 Hetero ring compound |